A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialed by clinicians and ...
Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...
The company, which secured $200 million from investors in a private funding deal last week, learned Tuesday of a serious side ...
Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...
Neurogene ( NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...
When looking at Neurogene’s stock performance year-to-date, it’s hard to ignore the impressive +269.09% increase. However, this recent downturn suggests that the market is responding to something ...
Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...
A stunning image of the Wallace Monument at sunset has won a Redding photographer a national award. Thomas Lamont – known ...
A new treatment that could prevent blindness in children with the CLN2 type Batten disease has been trialled by clinicians and researchers at UCL and Great Ormond Street Hospital (GOSH). The study, ...
US equity futures were flat before Tuesday's opening bell, with sentiment stabilizing after last week's election-fueled rally, while traders looked ahead to the consumer inflation report. The Dow ...
Stock futures were slightly up on Tuesday, easing after a post-election rally that had pushed markets to record highs. Here ...